

Disclosures

Personal Commercial (6)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Antag Pharma	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Arrhythmias and Clinical EP</i>
argenx BV	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Arrhythmias and Clinical EP</i>
Elsevier	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Arrhythmias and Clinical EP</i>
Regeneron	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Arrhythmias and Clinical EP</i>
STAT Health	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Arrhythmias and Clinical EP</i>
Theravance, Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (5)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Canadian Cardiovascular Society <i>† I am on the Board</i>	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	<i>General Cardiology</i>
Dysautonomia International <i>† Non-profit patient advocacy group</i>	Research/Research Grants <i>‡ -LDN for POTS RCT; Ivabradine vs Propranolol Comparative Effectiveness study; CMR in POTS study</i>	Significant (>= \$5,000)	<i>Arrhythmias and Clinical EP</i>
Heart and Stroke Foundation of Canada <i>† Not commercial; Foundation Peer Reviewed Grant</i>	Research/Research Grants	Significant (>= \$5,000)	<i>Arrhythmias and Clinical EP</i>
Long COVID Web <i>† CIHR funded research network</i>	Research/Research Grants <i>‡ Effect of Volume Expansion on Cognitive Impairment in Long COVID</i>	Significant (>= \$5,000)	<i>Arrhythmias and Clinical EP</i>
Standing Up to POTS <i>† Non-profit patient advocacy group</i>	Research/Research Grants <i>‡ Effect of Hyperventilation on Tachycardia in POTS</i>	Significant (>= \$5,000)	<i>Arrhythmias and Clinical EP</i>

Clinical Trial Enroller (2)

Trial Name	Trial Sponsor	Trial Funding Source
Product Surveillance Registry	MEDTRONIC	
Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure	Theravance, Inc.	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/2/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/2/2024

Embargo | Signed on 10/2/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 10/2/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.